382148 | Histone Deacetylase Inhibitor II - CAS 174664-65-4 - Calbiochem

382148
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₁₀H₁₀N₂O₄ 174664-65-4

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      382148-5MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Plastic ampoule 5 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma.
          Catalogue Number382148
          Brand Family Calbiochem®
          SynonymsCBHA, m-Carboxycinnamic Acid bis-Hydroxamide
          References
          ReferencesCoffey, D.C., et al. 2001. Cancer Res. 61, 3591.
          Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
          Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
          Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
          Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
          Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.
          Product Information
          CAS number174664-65-4
          ATP CompetitiveN
          DeclarationNot available for sale in the United States.
          FormOff-white solid
          Hill FormulaC₁₀H₁₀N₂O₄
          Chemical formulaC₁₀H₁₀N₂O₄
          ReversibleN
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetHDAC
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          382148

          References

          Reference overview
          Coffey, D.C., et al. 2001. Cancer Res. 61, 3591.
          Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
          Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
          Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
          Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
          Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision12-April-2011 RFH
          SynonymsCBHA, m-Carboxycinnamic Acid bis-Hydroxamide
          DescriptionA cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma cells, which can be blocked by Caspase Inhibitor Z-VAD-FMK (Cat. No. 627610).
          FormOff-white solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number174664-65-4
          Chemical formulaC₁₀H₁₀N₂O₄
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (50 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
          Toxicity Standard Handling
          ReferencesCoffey, D.C., et al. 2001. Cancer Res. 61, 3591.
          Coffey, D.C., et al. 2000. Pediatr. Oncol. 35, 577.
          Marks, P.A., et al. 2000. J. Natl. Cancer Inst. 92, 1210.
          Glick, R.D., et al. 1999. Cancer Res. 59, 4392.
          Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 3003.
          Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 5705.